[ad_1]
The new treatment will use an Emergent platform established in partnership with The Biomedical Advanced Research and Development Authority, a federal health agency, for anthrax and smallpox vaccine complications. BARDA awarded Emergent a $14.5 million grant for the plasma research, The Sun reported last year.
[ad_2]
Source link
Source: Baltimore Sun